Biogen

Biogen is a global biotechnology company pioneering therapies for serious neurological and neurodegenerative diseases. Founded by prominent scientists including Nobel Prize winners, it has grown from a venture capital-backed startup into one of the world's oldest independent biotechnology firms. The company's commercial portfolio and research pipeline focus on conditions such as multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis.

History

The company was established in 1978 by an international consortium of scientists, including Walter Gilbert, Kenneth Murray, and Phillip Allen Sharp, with early laboratories in Geneva and a corporate office in Cambridge, Massachusetts. Its initial research leveraged recombinant DNA technology, leading to early successes like recombinant interferon and a hepatitis B vaccine developed with the University of Washington and Merck & Co.. A pivotal moment came in 1996 with the U.S. Food and Drug Administration approval of AVONEX, its first therapy for relapsing-remitting multiple sclerosis. Major growth continued through the 2000s, including a 2003 merger with IDEC Pharmaceuticals, which added the cancer drug Rituxan to its portfolio, and the 2013 launch of TECFIDERA, a leading oral multiple sclerosis treatment.

Products and pipeline

The commercial portfolio is anchored by therapies for multiple sclerosis, including AVONEX, TECFIDERA, Plegridy, and VUMERITY. A significant product is SPINRAZA, the first approved treatment for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals. In 2021, the company gained accelerated approval from the U.S. Food and Drug Administration for ADUHELM, a controversial treatment for Alzheimer's disease. The clinical pipeline includes investigational drugs for conditions such as depression (zuranolone, developed with Sage Therapeutics), amyotrophic lateral sclerosis, and Parkinson's disease, alongside ongoing development in gene therapy and biomarker research.

Research and development

Research efforts are concentrated on neuroscience, targeting the underlying biology of diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The company utilizes advanced modalities including antisense oligonucleotide technology, as seen in the collaboration with Ionis Pharmaceuticals for SPINRAZA, and monoclonal antibody approaches for neurodegenerative conditions. It operates major research facilities in Cambridge, Massachusetts, and collaborates extensively with academic institutions such as Harvard University, the University of California, San Francisco, and Stanford University. Key scientific partnerships also include work with the Broad Institute and Denali Therapeutics on novel therapeutic targets.

Corporate affairs

The company is headquartered in Cambridge, Massachusetts, and is a constituent of the NASDAQ-100 and the S&P 500 indices. Its global operations span North America, Europe, and Asia. Leadership has included CEOs such as James C. Mullen and Michel Vounatsos, with Christopher A. Viehbacher appointed in 2022. The corporate structure has been shaped by significant transactions, including the spin-off of its hemophilia business into Bioverativ in 2017, which was later acquired by Sanofi. It maintains a large-scale manufacturing network with facilities in locations like Research Triangle Park, North Carolina, and Solothurn, Switzerland.

Controversies and legal issues

The approval and launch of ADUHELM in 2021 generated substantial controversy, with debates over the drug's clinical efficacy, its high annual cost, and the U.S. Food and Drug Administration's advisory committee process, leading to a congressional investigation by the House Committee on Oversight and Reform. The company has faced significant legal challenges, including a $900 million settlement in 2012 with the U.S. Department of Justice over allegations related to the promotion of Rituxan. It has also been involved in numerous patent disputes, such as litigation concerning TECFIDERA with competitors like Mylan and Banner Life Sciences, and has settled lawsuits related to SPINRAZA pricing with entities like the Service Employees International Union.

Category:Biotechnology companies of the United States Category:Companies listed on NASDAQ Category:Pharmaceutical companies established in 1978